PI3K/Akt信号通路抑制剂在妇科恶性肿瘤治疗中的研究进展
Research Progress on Inhibitors of PI3K/Akt Signaling Pathway in the Treatment of Gynecological Malignant
摘要: PI3K/Akt信号通路在细胞生长、增殖、迁移、代谢和分泌等各种细胞调控过程中起着至关重要的作用。PI3K/Akt信号转导是一种致癌途径，多项研究表明，PI3K/Akt信号转导的激活有利于增加肿瘤细胞的增殖和转移以及诱导治疗耐药性，这使得PI3K/Akt信号通路可成为肿瘤诊断及治疗的新靶点之一，因此，该通路的药物靶点有望成为癌症防治的有效临床治疗方法。PI3K/Akt信号通路抑制剂包括泛PI3K抑制剂(pan-PI3Ki)、亚型特异性PI3K抑制剂(IS PI3Ki)、双PI3K/mTOR抑制剂和Akt抑制剂。其中泛PI3K抑制剂是研究最多的药物。本文综述了PI3K/Akt信号通路抑制剂在疾病中的分子机制及其与妇科恶性肿瘤的关系，为妇科恶性肿瘤的治疗提供新的选择。
Abstract: The PI3K/Akt signaling pathway plays a crucial role in various cellular regulatory processes such as cell growth, proliferation, migration, metabolism and secretion. PI3K/Akt signal transduction is a carcinogenic pathway. Multiple studies have shown that activation of PI3K/Akt signal transduction is conducive to increasing the proliferation and metastasis of tumor cells and inducing therapeutic resistance, which makes the PI3K/Akt signaling pathway a new target for tumor diagnosis and treatment. Therefore, drug targets of this pathway are expected to become effective clinical therapies for cancer prevention and treatment. PI3K/Akt signaling pathway inhibitors include pan-PI3K inhibitors (panPI3Ki), subtype-specific PI3K inhibitors (ISPI3Ki), dual PI3K/mTOR inhibitors and Akt inhibitors. PanPI3K inhibitors are the most studied of these drugs. This article reviews the molecular mechanism of PI3K/Akt signaling pathway inhibitors in diseases and their relationship with gynecologic malignancies, providing a new option for the treatment of gynecologic malignancies.
文章引用：王萌倩, 刘开开, 刘芯瑜, 张晓露, 李红霞. PI3K/Akt信号通路抑制剂在妇科恶性肿瘤治疗中的研究进展[J]. 世界肿瘤研究, 2024, 14(1): 35-40. https://doi.org/10.12677/WJCR.2024.141006

参考文献

[1] Guo, X., Zhang, J., Shang, J., Cheng, Y., Tian, S. and Yao, Y. (2023) Human Leukocyte Antigen-G in Gynaecological Tumours. International Journal of Immunogenetics, 50, 163-176. [Google Scholar] [CrossRef] [PubMed]
[2] Shi, X., Wang, J., Lei, Y., Cong, C., Tan, D. and Zhou, X. (2019) Research Progress on the PI3K/AKT Signaling Pathway in Gynecological Cancer (Review). Molecular Medicine Reports, 19, 4529-4535. [Google Scholar] [CrossRef] [PubMed]
[3] Dibble, C.C. and Cantley, L.C. (2015) Regulation of mTORC1 by PI3K Signaling. Trends in Cell Biology, 25, 545-555. [Google Scholar] [CrossRef] [PubMed]
[4] Diaz-Padilla, I., et al. (2012) Biologic Rationale and Clinical Activity of mTOR Inhibitors in Gynecological Cancer. Cancer Treatment Reviews, 38, 767-775. [Google Scholar] [CrossRef] [PubMed]
[5] Osaki, M., Oshimura, M. and Ito, H. (2004) PI3K-Akt Pathway: Its Functions and Alterations in Human Cancer. Apoptosis, 9, 667-676. [Google Scholar] [CrossRef] 
[6] Passirani, C., Vessières, A., La Regina, G., Link, W. and Silvestri, R. (2022) Modulating Undruggable Targets to Overcome Cancer Therapy Resistance. Drug Resistance Updates, 60, Article ID: 100788. [Google Scholar] [CrossRef] [PubMed]
[7] Mayer, I.A. and Arteaga, C.L. (2016) The PI3K/AKT Pathway as a Target for Cancer Treatment. Annual Review of Medicine, 67, 11-28. [Google Scholar] [CrossRef] [PubMed]
[8] Margaria, J.P., Ratto, E., Gozzelino, L., Li, H. and Hirsch, E. (2019) Class II PI3Ks at the Intersection between Signal Transduction and Membrane Trafficking. Biomole-cules, 9, Article No. 104. [Google Scholar] [CrossRef] [PubMed]
[9] Li, Q., Li, Z., Luo, T. and Shi, H. (2022) Tar-geting the PI3K/AKT/mTOR and RAF/MEK/ERK Pathways for Cancer Therapy. Molecular Biomedicine, 3, Article No. 47. [Google Scholar] [CrossRef] [PubMed]
[10] Fergusson, A.D., Zhang, R., Riffle, J.S. and Davis, R.M. (2023) Encapsulation of PI3K Inhibitor LY294002 within Polymer Nanoparticles Using Ion Pairing Flash Nanoprecipi-tation. Pharmaceutics, 15, Article No. 1157. [Google Scholar] [CrossRef] [PubMed]
[11] Lenz, G., Hawkes, E., Verhoef, G., Haioun, C., Thye Lim, S., Seog Heo, D., et al. (2020) Single-Agent Activity of Phosphatidylinositol 3-Kinase Inhibition with Copanlisib in Patients with Molecularly Defined Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Leukemia, 34, 2184-2197. [Google Scholar] [CrossRef] [PubMed]
[12] Savas, P., Lo, L.L., Luen, S.J., Blackley, E.F., Callahan, J., Moodie, K., et al. (2022) Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study. Cancer Discovery, 12, 2058-2073.
[13] Jones, R.H., Casbard, A., Carucci, M., Cox, C., Butler, R., Alchami, F., et al. (2020) Fulvestrant plus Capivasertib versus Placebo after Relapse or Progression on an Aromatase Inhibitor in Metastatic, Oestrogen Receptor-Positive Breast Cancer (FAKTION): A Multicentre, Randomised, Controlled, Phase 2 Trial. The Lancet Oncology, 21, 345-357. [Google Scholar] [CrossRef] 
[14] Sidaway, P. (2023) Capivasertib Delays Disease Progression. Nature Reviews Clinical Oncology, 20, 579. [Google Scholar] [CrossRef] [PubMed]
[15] Sorolla, M.A., Parisi, E. and Sorolla, A. (2020) Determinants of Sensitivity to Radiotherapy in Endometrial Cancer. Cancers (Basel), 12, Article No. 1906. [Google Scholar] [CrossRef] [PubMed]
[16] Xie, P., et al. (2019) TRAF4 Promotes Endometrial Cancer Cell Growth and Migration by Activation of PI3K/AKT/ Oct4 Signaling. Experimental and Molecular Pathology, 108, 9-16. [Google Scholar] [CrossRef] [PubMed]
[17] Liao, J., Chen, H., Qi, M., Wang, J. and Wang, M. (2022) MLLT11-TRIL Complex Promotes the Progression of Endometrial Cancer through PI3K/AKT/mTOR Signaling Path-way. Cancer Biology & Therapy, 23, 211-224. [Google Scholar] [CrossRef] [PubMed]
[18] Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., et al. (2010) MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemo-therapeutic Agents or Molecular Targeted Drugs in Vitro and in Vivo. Molecular Cancer Therapeutics, 9, 1956-1967. [Google Scholar] [CrossRef] 
[19] Che, Y., Li, Y., Zheng, F., et al. (2019) TRIP4 Promotes Tumor Growth and Metastasis and Regulates Radiosensitivity of Cervical Cancer by Activating MAPK, PI3K/AKT, and hTERT Signaling. Cancer Letters, 28, 1-13. [Google Scholar] [CrossRef] [PubMed]
[20] Yap, T.A., Garrett, M.D., Walton, M.I., Raynaud, F., de Bono, J.S. and Workman, P. (2008) Targeting the PI3K-AKT- mTOR Pathway: Progress, Pitfalls, and Promises. Current Opinion in Pharmacology, 8, 393-412. [Google Scholar] [CrossRef] [PubMed]
[21] Aoki, M. and Fujishita, T. (2017) Oncogenic Roles of the PI3K/AKT/mTOR Axis. Current Topics in Microbiology and Immunology, 407, 153-189. [Google Scholar] [CrossRef] [PubMed]
[22] Cheaib, B., Auguste, A. and Leary, A. (2015) The PI3K/Akt/mTOR Pathway in Ovarian Cancer: Therapeutic Opportunities and Challenges. Chinese Journal of Cancer, 34, 4-16. [Google Scholar] [CrossRef] [PubMed]
[23] Ediriweera, M.K., Tennekoon, K.H. and Samarakoon, S.R. (2019) Role of the PI3K/AKT/mTOR Signaling Pathway in Ovarian Cancer: Biological and Therapeutic Significance. Seminars in Cancer Biology, 59, 147-160. [Google Scholar] [CrossRef] [PubMed]
[24] van der Ploeg, P., Uittenboogaard, A., Thijs, A.M.J., West-geest, H.M., Boere, I.A., Lambrechts, S., van de Stolpe, A., Bekkers, R.L.M. and Piek, J.M.J. (2021) The Effectiveness of Monotherapy with PI3K/AKT/mTOR Pathway Inhibitors in Ovarian Cancer: A Meta-Analysis. Gynecologic Oncolo-gy, 163, 433-444. [Google Scholar] [CrossRef] [PubMed]
[25] Chu, X., Lou, J., Yi, Y., Zhong, L. and Huang, O. (2023) Knockdown of ARHGAP30 Inhibits Ovarian Cancer Cell Proliferation, Migration, and Invasiveness by Suppressing the PI3K/AKT/mTOR Signaling Pathway. European Journal of Histochemistry, 67, 3653. [Google Scholar] [CrossRef] [PubMed]
[26] Mak, V.C., Wong, O.G., Siu, M.K., Wong, E.S., Ng, W.Y., Wong, R.W., Chan, K.K., Ngan, H.Y. and Cheung, A.N. (2015) FBI-1 Is Overexpressed in Gestational Trophoblastic Disease and Promotes Tumor Growth and Cell Aggressiveness of Choriocarcinoma via PI3K/Akt Signaling. The American Journal of Pathology, 185, 2038-2048. [Google Scholar] [CrossRef] [PubMed]
[27] Shih, I.M. (2007) Gestational Trophoblastic Neo-plasia—Pathogenesis and Potential Therapeutic Targets. The Lancet Oncology, 8, 642-650. [Google Scholar] [CrossRef] 

为你推荐